EarningsQ2 2024 Earnings Report

Diaceutics (7DC) Q2 2024 Earnings Report

0 Followers

Previous Report: Q4 2023

Next Report: Q4 2024

DE:7DC Q2 2024 EPS Results

Actual EPS-€0.04

Consensus EPS-€0.04

Beat/MissBeat by +<€0.01

One Year Ago EPS-€0.02

DE:7DC Q2 2024 Revenue Results

Actual Revenue€14.33M

Expected Revenue€14.30M

Beat/MissBeat by +€23.26K

YoY Revenue Growth+24.14%

Earnings Announcement Details

QuarterQ2 2024

Date09/17/2024

TimeBefore Open

Conference CallTuesday, September 17, 2024

DE:7DC Upcoming Earnings

Diaceutics's next earnings date is estimated for March 15, 2027, based on past reporting schedules.

Q2 2024 Earnings Call Audio

DE:7DC Q2 2024 Earnings Call

0:00 / 0:00

Q2 2024 Earnings Slide Deck

Q2 2024 Earnings Call Summary

Q2 2024

Earnings Call Date:Sep 17, 2024|

% Change Since:

Earnings Call Sentiment|Positive

The earnings call presented a mix of positive developments, particularly with revenue growth, high gross margins, and the strategic launch of the PMx solution, alongside record order book figures. However, challenges such as the increased EBITDA loss and decreased TCV were noted. The overall sentiment leans towards optimism, driven by strategic advancements and strong financial positioning.

Company Guidance

In the Q2 2024 earnings call for Diaceutics, CEO Ryan Keeling detailed significant advancements achieved in the first half of the year, particularly emphasizing the launch of their PMx solution. The company has expanded its lab network, notably integrating rare disease data and enhancing European data capabilities, all contributing to a robust and automated data pipeline. This automation, aided by AI, has streamlined data handling from extraction to customer delivery. The PMx solution, which emerged as a pivotal development, has transformed their approach by directly engaging physicians with patient data, boosting engagement and conversion rates. The financial health of the company is strong, with a 24% revenue increase to £12.3 million and a gross profit margin of 87%. Diaceutics aims to transition to a 70% subscription-led revenue model by 2025, with recurring revenues currently at 55%. The company also reported a record order book of £27.9 million, with plans to achieve profitability and free cash flow generation by 2025.

Revenue Growth

Revenue increased to GBP 12.3 million, up 24% or 28% on a constant currency basis, with 55% of revenue now being subscription-based.

High Gross Margin

Gross profit margins in H1 were 87%, with expectations to maintain around 85% for the full year.

PMx Launch

Launched the PMx solution which integrates the last 2 years of investment, offering a GBP 2 million per year per brand revenue potential, with higher levels of conversion and patient engagement.

Enterprise-wide Engagements

Increased the number of enterprise-wide engagements from 4 to 7 since FY '23, representing a key area of growth.

Strong Balance Sheet

Cash reserves of GBP 16.7 million with no debt, projecting a low point of GBP 13 million by year-end.

Record Order Book

Order book at a record high of GBP 27.9 million, providing 71% visibility of full-year consensus analyst guidance revenue.

DE:7DC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Mar 15, 2027	2026 (Q4)	0.04 / -	0.035	―
Sep 22, 2026	2026 (Q2)	-0.03 / -0.04	-0.033	-17.86% (>-0.01)
May 26, 2026	2025 (Q4)	0.03 / 0.03	0.012	200.00% (+0.02)
Sep 23, 2025	2025 (Q2)	-0.03 / -0.03	-0.036	9.68% (<+0.01)
May 13, 2025	2024 (Q4)	0.02 / 0.01	-0.003	433.33% (+0.02)
Sep 17, 2024	2024 (Q2)	-0.04 / -0.04	-0.021	-72.22% (-0.02)
May 21, 2024	2023 (Q4)	<0.01 / >-0.01	0.021	-116.67% (-0.02)
Sep 26, 2023	2023 (Q2)	- / -0.02	-0.01	-100.00% (-0.01)
Apr 17, 2023	2022 (Q4)	0.02 / 0.02	0.013	63.64% (<+0.01)
Sep 27, 2022	2022 (Q2)	- / -0.01	-0.005	-125.00% (>-0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed